from the earlier period. The main impulsion were continued expansion both merchandise exports and tourism. The value of merchandise exports, consistent with the faster economic growth among Thailand’s

Netherlands due to delay in the brownfield expansion, further reduction in PET and PTA production in the Netherlands (FM in 4Q18), unplanned shutdown in Poland (PET 4Q18), further normalization of IPA margin

manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international standards ISO 9001:2008, GMP, PICS, HACCP และ HALAL. Presently, At-Ze

located in Muang district, Chachoengsao province and authorized manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international

, At-Ze distributed medical care products under brand name “Aesthetic Zecret”. Factory is located in Muang district, Chachoengsao province and authorized manufacturing cosmeceuticals and modern medicine

dialysate and medical supply manufacturing and distribution, which increased from the same period of the previous year for 5.31 million baht or 22.37%, resulting in the increase of the Company Group’s gross

improve from spending in all categories, consistent with the expansion of manufacturing production in both domestic and export-related industries. Exports in the first three months have jumped 11.3% year on

expanded in all categories. The expansion in global and domestic demand reflect to the growth of manufacturing sector. In term of public spending and private investment which strongly growth in all sector

medical supply manufacturing and distribution, which increased from the same period of the previous year for 4.80 million baht or 18.99%, resulting in the increase of the Company Group’s gross profit for

-123.26 -70.72% Operating results for each business segment are shown below: 1. Manufacturing and Selling of Special Cutting Tools unit: THB million 2019 2018 Change (THB million) Change (%) Revenue from